PMMA
4-methoxymethamphetamine
Viewing r1 — Apr 25, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
PMMA (para-methoxymethamphetamine) is a synthetic stimulant of the substituted amphetamine class. It is the N-methyl derivative of PMA, sharing its dangerous serotonergic profile. It raises serotonin in the brain while blocking the enzyme that breaks serotonin down — producing physiological activation without euphoria.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
PMMA was first studied in animals in 1988[1] and documented by Alexander Shulgin in 1991, who found no psychoactivity at active doses.[2] Mass-casualty deaths in Norway and Canada linked to counterfeit ecstasy tablets established it as one of the most dangerous adulterants in the illicit drug supply.[3][4] It is controlled internationally and has no accepted medical use.
Subjective effects include rapid heart rate, compulsive yawning, nausea, and dangerous overheating.[2] The experience is defined by absence — physical burden without the euphoria, empathy, or perceptual shift that MDMA produces. At toxic doses, body temperature rises to life-threatening levels, and seizures and cardiovascular collapse follow.[3]
No dependence data exist; the margin between an active and a fatal dose is among the narrowest of any recreational drug.[3] Slow onset encourages redosing before peak effects arrive, and the dual mechanism — serotonin release plus enzyme blockade — can produce lethal serotonin overload.[5][6] What is known comes almost entirely from forensic case reports and animal studies.
History[edit]
Discovery
PMMA was first studied in animals in 1988, where researchers found it produced neither stimulant nor hallucinogenic effects.[1] Alexander Shulgin tested it at 110 mg in 1991 and reported tachycardia and physical discomfort but no psychoactive effect.[2] He catalogued it as "METHYL-MA" in PiHKAL and explicitly discouraged further human experimentation, citing animal data showing catatonia and unsuspected neurochemical changes.
Illicit market emergence
PMMA appeared on European drug markets in the late 1990s as pressed tablets sold as ecstasy. By 2002, the EU had documented nearly 19,000 tablets seized across 15 member states, with at least three associated deaths.[7] The EU placed it under controls in February 2002 — the first major international scheduling action for the compound.
Mass-casualty events
The Norwegian "PMMA epidemic" of 2010–2011 killed 12 people and hospitalised 22 more over six months; the implicated tablets were known as "Death".[3] A parallel wave struck western Canada in 2011, producing 21 fatalities across Alberta and British Columbia.[4] Additional deaths have been documented in Germany,[8] Ireland,citation needed Scotland,citation needed and Argentina.
The name PMMA derives from its systematic designation as para-methoxy-N-methylamphetamine; Shulgin catalogued it as "METHYL-MA" in PiHKAL, reflecting its structural relationship to MA (PMA). PMMA's precursors — including 4-methoxyphenyl-2-propanone, obtainable from trans-anethole extracted from star anise — are unrestricted chemicals in many jurisdictions,[9] a factor that has repeatedly enabled clandestine production. The compound has no recreational identity of its own; it is known exclusively as a dangerous contaminant of the MDMA supply.
Chemistry[edit]
Structural class
PMMA belongs to the substituted amphetamine family — specifically the para-methoxy series, characterised by serotonergic activity and MAO-A inhibition rather than the dopaminergic stimulation of classical amphetamines.
It is the N-methyl derivative of PMA and the 4-methoxy structural analog of methamphetamine; a single methoxy group at the para position of the aromatic ring shifts the pharmacology entirely toward serotonin. Its molecular formula is C₁₁H₁₇NO (molecular weight 179.26 g/mol).
Pharmacology[edit]
Mechanism of action
PMMA works through two converging serotonin-focused mechanisms that together explain its disproportionate danger.[6][10] It enters serotonin transporters and triggers serotonin release — preferring serotonin over dopamine.[11][6] It also inhibits MAO-A, the enzyme that normally breaks serotonin down,[10] so the serotonin it releases accumulates rather than clearing.
The combination — release plus blocked clearance — produces a serotonin overload that a single-mechanism drug could not generate at the same dose.[6][12] This is why PMMA can trigger the life-threatening overheating and seizure response of serotonin syndrome at doses that might otherwise be survivable.
Pharmacokinetics
No human pharmacokinetic studies have been conducted. In rats, blood concentrations peak around 30 minutes but brain concentrations peak around 60 minutes at higher doses[5] — the drug appears inactive before its full brain effect develops. PMMA is broken down by the CYP2D6 enzyme;[13] people with genetic variants that slow this enzyme face elevated toxicity at any dose.
Neuroscience[edit]
Where it acts
PMMA raises serotonin and dopamine in the striatum and frontal cortex.[12] Unlike MDMA, it increases serotonin in the striatum while decreasing cortical dopamine — a dissociation that may contribute to its comparatively weak subjective effects.
Dangerous overheating occurred in rats only under crowded conditions, not in isolated housing.[5] Nearly all human PMMA deaths have occurred in hot, crowded environments — raves, clubs, festivals. Ambient temperature and physical exertion amplify the lethal risk considerably.
Neurotoxicity
PMMA kills dopamine-producing neurons in the striatum of mice through a cellular stress pathway involving protein kinase C and inflammatory signalling.[14] This is distinct from MDMA neurotoxicity, which primarily damages serotonergic rather than dopaminergic neurons. Whether a single human exposure causes lasting brain damage has not been established.
Whether PMMA produces entactogenic effects in humans at any dose remains unanswered — Shulgin reported no psychoactivity at 110 mg,[2] yet animal data place PMMA in the MDMA-like stimulus class. Whether single human exposures cause the dopaminergic neuron loss demonstrated in mouse models[14] is unknown.
Subjective Effects[edit]
PMMA's experiential profile is dominated by physiology, not consciousness. The only documented human account — Shulgin's self-experiment at 100–110 mg — described cardiovascular stress and somatic discomfort with no euphoria, empathy, or perceptual change.[2] Animal drug discrimination data place it in the MDMA-like class,[15] but this pharmacological similarity has not produced confirmed entactogenic effects in any human account.
Compared to MDMA, PMMA delivers the physical cost without the reward. Where MDMA produces warmth, openness, and connection, PMMA produces tachycardia, yawning, and somatic distress. The slow onset — not any euphoric quality — is its most consequential feature, reliably encouraging redosing before effects peak.
Effect Grid
At common doses (100–120 mg oral), the full PMMA experience — such as it is — manifests primarily as physiological activation rather than psychoactivity. Tachycardia (pulse exceeding 100 bpm), compulsive yawning, and eye muscle disturbance resembling nystagmus were documented at 110 mg by Shulgin. No euphoria, empathy enhancement, or perceptual effects were reported.
Physical effects dominate: elevated heart rate and blood pressure, excessive sweating, possible bruxism, and pupil dilation. The onset is notably slow (estimated 45–90 minutes), and the disconnect between peripheral effects and absent central psychoactivity is characteristic. Total duration is approximately 3–5 hours.
The slow onset at this range is the most dangerous feature — users expecting MDMA-like effects within 30 minutes may redose before PMMA's full action develops, pushing total intake into the lethal range.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual drifting · Tracers
Dehydration sensation · Wakefulness · Pupil dilation · Vasoconstriction · Body high · Dry mouth · Heart rate perception changes · Insomnia · Restlessness · Dizziness · Bruxism · Sexual arousal suppression · Nausea · Muscle tension · Spontaneous body sensations · Seizure threshold reduction · Headache · Tactile euphoria · Tingling / electric sensations · Trembling · Vomiting
Body high · Dry mouth · Heart rate perception changes · Insomnia · Restlessness · Dizziness · Bruxism · Sexual arousal suppression · Nausea · Muscle tension · Spontaneous body sensations · Seizure threshold reduction · Headache · Tactile euphoria · Tingling / electric sensations · Trembling · Vomiting
Thought acceleration · Thought disorganization
Trust enhancement
Timeline
First perceptible effects: subtle increase in heart rate, mild restlessness. Onset is notably slower than MDMA, a critical distinction — the delay drives dangerous redosing behaviour.
Sympathomimetic activation builds: tachycardia becomes distinct, blood pressure rises, possible onset of sweating and jaw tension. Central psychoactive effects remain absent or minimal at common doses.
Maximum physiological activation: tachycardia (pulse >100 bpm), compulsive yawning, eye muscle disturbance. At 110 mg, Shulgin described physical effects resembling MDMA's body load without euphoria or empathogenic character.
Gradual return to baseline. Cardiovascular effects subside over 1–2 hours. Shulgin reported full resolution by approximately hour 4 at 110 mg.
Residual fatigue and possible mild malaise. No specific afterglow data published for PMMA.
⚠ Avoid driving or operating machinery for at least 6 hours after ingestion, as residual cardiovascular and cognitive effects may persist beyond subjective resolution.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- MDMA · PMA · amphetamine
Toxicity
Acute toxicity
PMMA carries critical acute toxicity risk. Over 40 deaths have been documented internationally, many from single-tablet ingestions.[3] The margin between non-fatal and fatal blood concentrations is barely one order of magnitude.
PMMA has caused over 40 documented deaths internationally. Fatal outcomes have occurred from single-tablet ingestions. The margin between active and lethal doses is extremely narrow, and there is no established safe dose range.
Death follows a characteristic sequence: agitation and autonomic instability escalate to dangerous overheating (body temperatures above 40°C), then seizures, cardiovascular collapse, and multi-organ failure.[3][4] Kidney failure has been documented in survivors.
Emergency treatment is supportive: aggressive cooling for hyperthermia, benzodiazepines for seizures and agitation, cyproheptadine for serotonin syndrome features. There is no specific antidote.
Polydrug synergistic toxicity
Most Norwegian fatalities involved polydrug use.[3] Depressants — alcohol, opioids, benzodiazepines — produced deaths at lower PMMA blood concentrations than PMMA alone. They appear to mask the early warning signs of serotonin syndrome while dangerous overheating continues unchecked.
Neurotoxicity
PMMA kills dopamine-producing neurons in the striatum of mice through a cellular stress pathway.[14] Whether single human exposures produce lasting brain damage has not been established.
Psychological risks
No systematic data on PMMA-specific psychological risks exist. Shulgin reported no psychoactive effects at 110 mg.[2] In fatal and near-fatal cases, agitation and delirium appear as features of serotonin syndrome[3] — these are medical emergencies, not primary psychological effects.
Tolerance & dependence
No data exist on PMMA-specific tolerance or dependence. As a serotonin-preferring releaser with weak dopaminergic activity, structural analogy to MDMA suggests low reinforcement potential — but this is inference, not direct evidence.[12]
Drug interactions
PMMA's dual mechanism — serotonin release plus MAO-A inhibition — creates a uniquely dangerous interaction profile. Any co-administered serotonergic agent adds to an already elevated serotonergic load.
Serotonergic combinations
Combining PMMA with any serotonin-active drug carries severe serotonin syndrome risk. Documented fatal combinations include PMMA with MDMA,[3][4] PMA,[8][7] and amphetamine. SSRIs, SNRIs, and MAOIs carry class-inferred extreme risk.
CYP2D6 inhibitors
PMMA is primarily broken down by CYP2D6.[13] Drugs that inhibit this enzyme — including fluoxetine, paroxetine, bupropion, haloperidol, and ritonavir — reduce PMMA clearance and could raise blood concentrations into the lethal range. Fluoxetine and paroxetine are both CYP2D6 inhibitors and serotonergic agents, compounding the risk through two independent mechanisms.
CNS depressants
PMMA combined with depressants — alcohol, opioids, benzodiazepines — produced fatalities at lower PMMA blood concentrations than PMMA alone in the Norwegian cases.[3] Depressants mask the early agitation and autonomic warning signs of developing serotonin syndrome, allowing dangerous overheating to progress undetected.
Stimulants
Co-ingestion of cocaine, amphetamine, or methamphetamine adds cardiovascular and hyperthermia risk.[4] Multiple synthetic amphetamines were co-present in the majority of Canadian fatalities.
Contraindications
Absolute contraindications
- MAOI therapy: Combining external monoamine oxidase inhibition with PMMA's own MAO-A inhibition creates near-certain serotonin syndrome
- SSRI/SNRI therapy: The combination of serotonin release, MAO-A inhibition, and reuptake blockade produces extreme serotonergic overload
- CYP2D6 poor metabolizer status: Genetically impaired clearance elevates blood concentrations and toxicity risk at any dose[13]
Relative contraindications
- Pre-existing heart conditions: PMMA causes tachycardia and cardiovascular stress[2][16]
- High blood pressure and hyperthyroidism: Sympathomimetic activity may worsen these conditions[16][17]
- Liver impairment: Reduces metabolic clearance, compounding CYP2D6-dependent elimination
- Kidney impairment: Reduces drug elimination via renal excretion[18]
- Pregnancy: Contraindicated as a sympathomimetic monoamine releaser
Harm Reduction[edit]
Forms & Identification
PMMA is found almost exclusively as pressed tablets sold as "ecstasy" or "MDMA," often co-formulated with PMA, MDMA, or other synthetic amphetamines.[9] These tablets are visually indistinguishable from legitimate MDMA tablets. Standard reagent kits cannot reliably distinguish PMMA from MDMA — quantitative drug checking services or laboratory analysis (GC-MS, FTIR) provide the only reliable identification.
Guidelines
- Test every tablet using a drug checking service with quantitative capability — reagent kits alone cannot reliably distinguish PMMA from MDMA
- Never redose based on MDMA timing expectations — PMMA's onset is significantly slower; wait at least 2–3 hours before concluding a dose is inactive
- Stay cool — avoid prolonged dancing, hot environments, and crowding; take regular breaks in cool areas and drink water at a moderate pace
- Disclose all medications — anyone taking antidepressants, antipsychotics, or HIV antiretrovirals (particularly CYP2D6 inhibitors) faces elevated risk from any dose
- Never use alone — ensure someone present is aware of what was taken and knows the signs of serotonin syndrome
Set & Setting
Most PMMA fatalities have occurred in crowded, hot environments — raves, clubs, and festivals — where ambient temperature, physical exertion, and dehydration compound the overheating risk.[5] PMMA's slow onset relative to MDMA creates a dangerous mismatch: users are most likely to redose in precisely the settings where doing so is most dangerous.
Aftercare & integration. PMMA exposure — whether intentional or accidental — is a physically taxing event dominated by cardiovascular and thermoregulatory stress. In the hours and days following exposure, prioritise rest, hydration, and gradual temperature regulation.
Monitor for delayed symptoms including muscle pain, dark urine (which may indicate kidney stress), or persistent elevated heart rate, and seek medical attention if any appear. PMMA does not produce the cognitive or emotional experiences associated with entactogens at sub-toxic doses, so there is no meaningful integration component in the psychedelic sense.
Recovery & Support
PMMA is not associated with physical dependence or compulsive use patterns. Repeated exposure is rare because most encounters are accidental — PMMA sold as MDMA — and the experience is unrewarding. If PMMA exposure is part of a broader pattern of stimulant or MDMA use, harm reduction services, peer support networks, and substance use counselling can address the underlying use pattern rather than PMMA specifically.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: body temperature you can feel through clothing, rigid muscles, seizures, confusion or delirium, loss of consciousness, or a rapid heart rate that does not settle with rest. Any of these after suspected PMMA ingestion is a medical emergency.
Immediate steps:
- Call emergency services immediately.
- Move the person to the coolest available environment.
- Remove excess clothing and apply cold water or ice packs to the neck, armpits, and groin.
- If unconscious but breathing, place in the recovery position.
- Do not induce vomiting. Do not give aspirin or paracetamol for fever — these do not work on drug-induced hyperthermia.
- Stay with the person until help arrives.
What to tell the dispatcher: The substance (suspected PMMA or PMA in an ecstasy tablet), the amount taken, when it was taken, and current symptoms — especially body temperature and seizure activity. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
PMMA is controlled in all major jurisdictions and has no accepted medical use anywhere. The EU placed it under controls in February 2002,[7] and it was added to Schedule I of the United Nations 1971 Convention on Psychotropic Substances in March 2016.[19]
Legal status varies by jurisdiction and changes over time. This information is not legal advice.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Placed in Schedule I effective 26 July 2021 by DEA final rule.[19] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled as a methamphetamine derivative.[20] |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Prohibited; no permitted medical use.[20] |
| European Union | Controlled (Council Decision, 28 February 2002) | All EU member states required to implement controls following 29 seizure incidents across 15 states.[7] |
| Germany | Anlage I (BtMG) | Controlled; authorised scientific use only.[20] |
| Brazil | F2 list | Controlled.[20] |
| Australia | Prohibited (schedule unconfirmed) | Classified as prohibited by the Alcohol and Drug Foundation;[16] specific Poisons Standard entry not confirmed.citation needed |
| United Nations | Schedule I (1971 Convention on Psychotropic Substances) | Added at 59th CND session, March 2016.[19] |
references
- [1] ^abGlennon RA, Ismaiel AE, Martin B, Poff D, Sutton M (1988) A preliminary behavioral investigation of PMMA, the 4-methoxy analog of methamphetamine — Pharmacology, Biochemistry, and Behavior PMID:3252264
- [2]
- [3]
- [4]
- [5] ^abcdPáleníček T, Balíková M, Rohanová M, Novák T, Horáček J, Fujáková M, Höschl C (2011) Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats — Pharmacology, Biochemistry, and Behavior doi:10.1016/j.pbb.2010.12.011
- [6] ^abcdLiechti ME (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling — Swiss Medical Weekly doi:10.4414/smw.2015.14043